Recent news on Deferasirox

FDA notifies healthcare professionals of changes to Exjade labeling  -  May 22, 2007
DG NewsROCKVILLE, MD -- May 22, 2007 -- Novartis and FDA notified healthcare professionals of changes to the WARNINGS and ADVERSE REACTIONS sections of the product

Novartis to count cost of generic Lotrel hitting market  -  May 23, 2007
Pharma Times (subscription),Meantime, Novartis and the FDA have alerted physicians to a label change for the firm's Exjade (deferasirox) for the treatment of iron overload as a result

Data Presented At The International Symposium On Myelodysplastic ...  -  May 18, 2007
Medical News Today (press release),There are some drugs which can help chelate, or bind to iron to help remove it from the body, such as deferoxamine and deferasirox, and can reduce the

Novartis off to a flyer in 2007 thanks to Diovan and Gleevec  -  Apr 24, 2007
Pharma Times (subscription),Exjade (deferasirox), the first once-daily oral iron chelator for chronic iron overload, contributed $65 million to Novartis' coffers. On the negative side,

New data support long term use of once – daily Exjade® to reduce ...  -  Mar 13, 2007
ArabianBusiness.com,New long term efficacy and safety data indicate that once-daily Exjade (deferasirox) continues to reduce total body iron over 2.5 years of treatment in a

Dubai Thalassemia Center Lauded at 5th Middle East Thalassemia ...  -  Feb 18, 2007
Al-Bawaba,Exjade(deferasirox), which can be taken in a drink, removes excess iron from key organs including the liver replacing the use of the cumbersome infusion

SMC Approves Exjade® - No More Needles In Scotland - Good News For ...  -  Feb 13, 2007
Medical News Today (press release),Novartis today welcomed the Scottish Medicines Consortium's acceptance of deferasirox (Exjade®) for use within NHS Scotland for the treatment of iron

Scotland rejects Pfizer's Sutent but backs Novartis' Exjade  -  Feb 13, 2007
Pharma Times (subscription),There was better news for Novartis as the SMC recommended Exjade (deferasirox) for the treatment of iron overload associated with of rare acquired or

Novartis Highlights Strong R&D Pipeline, Plans For Multiple New ...  -  Nov 29, 2006
Medical News Today (press release),Exjade (deferasirox) has been launched in the US and Europe as the first and only once-daily oral iron chelator for chronic iron overload in transfusion ...

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional